Research
Mixed
Long-term pharmacotherapy with orlistat, sibutramine, or rimonabant produces modest but statistically significant weight loss (approx. 3-5 kg) compared to placebo in adults with obesity or overweight.
If you have obesity or overweight with related health issues, long-term medication (orlistat, sibutramine, or rimonabant) combined with lifestyle changes can help you lose a modest amount of weight (3-5 kg) compared to doing nothing. This small loss is clinically beneficial for your health, even if it doesn't solve obesity entirely.
GoodSupportsHIGH confidence
Compared to placebo, orlistat reduced weight by 2.9 kg (95% confidence interval (CI) 2.5 to 3.2 kg), sibutramine by 4.2 kg (95% CI 3.6 to 4.7 kg), and rimonabant by 4.7 kg (95% CI 4.1 to 5.3 kg).
Why this rating
Cochrane systematic review of multiple RCTs, though limited by high attrition rates (30-40%).
Source
Long-term pharmacotherapy for obesity and overweight
Raj Padwal et al. · Cochrane Database of Systematic Reviews · 2003
DOI 10.1002/14651858.cd004094.pub2
Meta-analysis · 30 studiesCited 381×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Orlistat reduces the incidence of type 2 diabetes and improves cardiovascular risk factors (lipids, blood pressure, glycaemic control) in patients with diabetes, despite increasing gastrointestinal side effects.Good
- Sibutramine improves lipid profiles (HDL, triglycerides) but increases blood pressure and heart rate, while rimonabant improves lipid profiles and glycaemic control but increases the risk of mood disorders.Good
Related findings · Mixed
- Bariatric surgery (VSG and RYGB) is the most effective and sustainable treatment for obesity, producing marked and sustained weight loss that non-surgical interventions cannot match.Strong
- Severely protein-deficient diets (2–3% energy) induce lean body mass loss and metabolic imbalance, whereas adequate protein intake (0.66 g/kg/d minimum) is a prerequisite for maintaining muscle, bone, and physiological function.Strong
- For patients with Class III obesity (BMI >39.9 kg/m2), metabolic bariatric surgery (MBS) is significantly more effective than any currently approved medication, with BilioPancreatic Diversion (BPD) showing the highest estimated weight loss.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →